Docetaxel for the post-surgery treatment of patients with node-positive breast cancer

Therapeutics and Clinical Risk Management

Volumn 4, Issue 2, 2008, Pages 419-424

  Pant, Shubham ^a   Chilukuri, Meena P ^b   Ramaswamy, Bhuvaneswari ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b MOUNT CARMEL HEALTH SYSTEM   (United States)

Author keywords

Docetaxel; Node positive breast cancer; Post surgery treatment; Taxanes

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CIPROFLOXACIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIURETIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; METHOTREXATE; PACLITAXEL; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ADD ON THERAPY; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MECHANISM; DYSESTHESIA; EDEMA; ERYTHEMA; FEBRILE NEUTROPENIA; FEVER; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; LACRIMATION; LOW DRUG DOSE; LYMPH NODE METASTASIS; MACULOPAPULAR RASH; MONOTHERAPY; MORTALITY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAIL DYSTROPHY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ONYCHOLYSIS; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; POSTOPERATIVE CARE; RECURRENCE RISK; REVIEW; RISK REDUCTION; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN PRURITUS; SKIN TOXICITY; STOMATITIS; WEIGHT GAIN;

EID: 44049103763     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Bissery MC, Nohynek G, Sanderink GJ, et al. 1995. Docetaxel(Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs, 6:339-55, 363-8.
2. Bridgewater. 2004. Taxotere prescribing information. Aventis Pharmaceuticals Inc. NJ.
3. Cortes JE and Pazdur R. 1995. Docetaxel. J Clin Oncol, 13:2643-55.
4. Crown JP, Francis P, Di Leo A, et al. 2006. Docetaxel (T) given concurrently with or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+)breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIG 2-98 Trial at 5 years median follow-up (MFU). J Clin Oncol, 24(18S):Abstract 519.
5. Diaz JF and Andreu JM. 1993. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry, 32:2747-55.
6. Eiermann W, Pienkowski T, Crown J, et al. 2005. Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide versus doxorubicin and cyclophosphamide followed by docetaxel in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes. Proc SABCS: Abstract 1069.
7. Eisenhauer EA, Vermorken JB. 1998. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs, 55:5-30.
8. Esmaeli B, Valero V, Ahmadi MA, et al. 2001. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology, 108:994-5.
9. Esmaeli B. 2005. Management of excessive tearing as a side effect of docetaxel. Clin Breast Cancer, 5:455-7.
10. Hainsworth JD, Burris HA 3rd, Greco FA. 1999. Weekly administration of docetaxel (Taxotere): summary of clinical data. Semin Oncol, 26(Suppl 10):19-24.
11. Henderson IC, Berry DA, Demetri GD, et al. 2003. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 21:976-83.
12. Jones SE, Savin MA, Holmes FA, et al. 2006. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol, 24:5381-7.
13. Markman M. Managing taxane toxicities. 2003. Support Care Cancer, 11:144-7.
14. Martin M, Pienkowski T, Mackey J, et al. 2005. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med, 352:2302-13.
15. Michaud LB, Valero V, Hortobagyi G. 2000. Risks and benefits of taxanes in breast and ovarian cancer. Drug Safety, 23:401-28.
16. Piccart MJ, Klijn J, Paridaens R, et al. 1997. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol, 15:3149-55.
17. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. 2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353:1659-72.
18. Piedbois P-P, Serin D, Priou F, et al. 2005. AERO-B03: A randomized phase II trial of dose-dense, docetaxel in node-positive breast cancer. J Clin Oncol, 23(16S):Abstract 647.
19. Ravdin PM, Burris HA 3rd, Cook G, et al. 1995. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol, 13:2879-85.
20. Ringel I, Horwitz SB. 1991. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst, 83:288-91.
21. Roché H, Fumoleau P, Spielmann M, et al. 2006. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol, 24:5664-71.
22. Romond EH, Perez EA, Bryant J, et al. 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353:1673-84.
23. Schrijvers D, Wanders J, Dirix L, et al. 1993. Coping with toxicities of docetaxel (Taxotere). Ann Oncol, 4:610-11.
24. Slamon D, Eiermann W, Robert N, et al. 2005. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC⇒T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC⇒TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Proc SABCS:Abstract 1.
25. Slamon DJ, Leyland-Jones B, Shak S, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344:783-92.
26. Spielmann M, Roché H, Delozier T, et al. 2006. Safety analysis from PACS 04-A phase III trial comparing 6 cycles of FEC 100 with 6 cycles of ET75 for node-positive early breast cancer patients followed by sequential trastuzumab in HER2 patients: Preliminary results. J Clin Oncol, 24(18S):Abstract 632.
27. Trudeau M, Charbonneau F, Gelmon K, et al. 2005. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol, 6:886-98.
28. Valeria F, Ester E, Modesto D'Aprile, et al. 2001. A feasibilty study of a sequential dose-dense adjuvant regimen with epidoxorubicin followed by docetaxel followed by high-dose cyclophosphamide for early breast cancer with 4 or more lymph node metastases. Annals of Oncol, 12(4S):52.
29. Valero V, Holmes FA, Walters RS, et al. 1995. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol, 13:2886-94.
30. Valero V, Jones SE, Von Hoff DD, et al. 1998. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol, 16:3362-8.
31. Verschraegen CF, Sittisomwong T, Kudelka AP, et al. 2000. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol, 18:2733-9.
32. Vogel CL, Mackey JR, Martin M, et al. 2004. The role of growth factor support following neutropenic events n early stage breast cancer (BC) patients treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC): A sub-analysis of BCIRG 001. J Clin Oncol, 22(14S): Abstract 677.
33. Zimmerman GC, Keeling JH, Burris HA, et al. 1995. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol, 131:202-6.
34. Zimmerman GC, Keeling JH, Lowry M, et al. 1994. Prevention of docetaxel-induced erythrodysesthesia with local hypothermia. J Natl Cancer Inst, 86:557-8.